Similar articles

Abstract: Pure red cell aplasia (PRCA) is a well-recognized complication of ABO major mismatched allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reported incidence of 10%–20% (Zhidong et al., 2012; Busca et al., 2018). It is clinically characterized by anemia, reticulocytopenia, and the absence of erythroblasts in a normal-appearing bone marrow biopsy (Shahan and Hildebrandt, 2015). The mechanism for PRCA has been presumed to be persistence of recipient isoagglutinins, produced by residual host B lymphocytes or plasma cells, which can interfere with the engraftment of donor erythroid cells (Zhidong et al., 2012). Several risk factors of PRCA at presentation are known, such as presence of anti-A isoagglutinins before transplantation, reduced intensity conditioning, absence of acute graft-versus-host disease (GVHD), sibling donors, and cyclosporin A (CsA) as GVHD prophylaxis (Hirokawa et al., 2013). PRCA is not considered to be a barrier to HSCT, as some patients can recover spontaneously or benefit from various approaches including high-dose steroids, erythropoietin (EPO), plasma exchange, immunoadsorption, donor lymphocyte infusion (DLI), treatment with rituximab, bortezomib, or daratumumab, and tapering or discontinuation of immunosuppression (Hirokawa et al., 2013; Bathini et al., 2019). However, there are still some patients who fail to respond even to aggressive treatment; they become red cell transfusion-dependent and iron-overloaded, and their life quality is impaired.

艾曲波帕成功治疗ABO血型不合的异基因造血干细胞移植后难治性纯红细胞再生障碍性贫血

[1]AlvaradoLJ, HuntsmanHD, ChengH, et al., 2019. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood, 133(19):2043-2055.

[2]BaoWL, BusselJB, HeckS, et al., 2010. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood, 116(22):4639-4645.

[3]BathiniS, HoltzmanNG, KokaR, et al., 2019. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol, 94(8):E216-E219.

[4]BuscaA, DellacasaC, GiacconeL, et al., 2018. Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 24(8):1765-1770.

[5]DesmondR, TownsleyDM, DumitriuB, et al., 2014. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood, 123(12):1818-1825.

[6]GaoF, ZhouXY, ShiJM, et al., 2020. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia. Ann Hematol, 99(11):2679-2687.

[7]GuentherKL, CherukuPS, CashA, et al., 2019. Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells. Exp Hematol, 73:1-6.e6.

[8]HirokawaM, FukudaT, OhashiK, et al., 2013. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant, 19(7):1026-1032.

[9]OlnesMJ, ScheinbergP, CalvoKR, et al., 2012. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med, 367(1):11-19.

[10]SackettK, CohnCS, Fahey-AhrndtK, et al., 2018. Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. J Clin Apher, 33(1):108-112.

[11]SelleriC, RaiolaA, de RosaG, et al., 1998. CD34⁺-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant, 22(6):605-607.

[12]ShahanJL, HildebrandtGC, 2015. Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma. Transfus Med, 25(5):342-344.

[13]VlachodimitropoulouE, ChenYL, GarbowskiM, et al., 2017. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood, 130(17):1923-1933.

[14]YangX, LevisM, 2014. Pulsed-high-dose dexamethasone as a treatment for pure red cell aplasia following ABO-incompatible allogeneic stem cell transplantation. Transfus Med, 24(4):246-248.

[15]ZhaoZ, SunQ, SokollLJ, et al., 2018. Eltrombopag mobilizes iron in patients with aplastic anemia. Blood, 131(21):2399-2402.

[16]ZhidongW, HongminY, HengxiangW, 2012. Successful treatment of pure red cell aplasia with a single low dose of rituximab in two patients after major ABO incompatible peripheral blood allogeneic stem cell transplantation. Transfus Med, 22(4):302-304.